ClinicalTrials.gg
CompletedNCT01911429Updated Apr 18, 2017Results posted

Pediatric Schizophrenia Efficacy and Safety Study

A Phase 3 interventional study of Lurasidone 40 mg and Lurasidone 80 mg in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 90 sites in 17 countries. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-04-18.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
12th of 39
327 · median 149
Started
2013
with 4 others
Phase 3
18 of 39
none open now
Registered
26th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 12th largest by enrollment, is one of 5 that started in 2013, is one of 18 in phase 3, and was the 26th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

Efficacy and Safety study of Lurasidone in pediatric patients.

Read the detailed description

To evaluate the efficacy of lurasidone (40 mg/day and 80 mg/day) compared with placebo in adolescent subjects with schizophrenia (diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria) as measured by the change from Baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' adherence to the study procedures must be obtained for subjects who are not emancipated. In accordance with Institutional Review Board (IRB) requirements, the subject will complete an informed assent prior to study participation.
  • Male or female subjects 13 to 17 years of age, inclusive, at the time of consent.
  • axis I primary diagnosis of schizophrenia (including disorganized (295.10), paranoid (295.30), undifferentiated (295.90) subtypes) and confirmation of the schizophrenia diagnosis by an adequately trained clinician at the time of screening, by means of the Schedule for Affective Disorders and Schizophrenia for School-age Children (K-SADS-PL).
  • PANSS total score ≥ 70 at screening and Baseline.
  • CGI-S ≥ 4 at screening and Baseline.
  • Within 5th to 95th percentile for gender specific weight-for-age and height-for-age Growth Charts from National Center for Health Statistics.
  • In good physical health on the basis of medical history, physical examination, and laboratory screening.
  • Females who participate in this study:

are unable to become pregnant (eg, premenarchal, surgically sterile, etc.); -OR-

practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 30 days after the last dose of study drug has been taken;

-OR-

are sexually active and willing to use a medically effective method of (e.g., male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.

  • Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 30 days after the last dose of study drug has been taken.
  • In the judgement of the clinician, the subject has an acute exacerbation of psychotic symptoms (no longer than 2 months in duration) and marked deterioration of function from baseline (by history) or, the subject has been hospitalized for the purpose of treating an acute psychotic exacerbation for 2 consecutive weeks or less immediately before screening.
  • In the judgment of the investigator, the subject is able to swallow the size and number of study drug tablets specified per protocol.
  • Willing and able to adhere to protocol-specified meal requirements during dosing.

Exclusion criteria

Exclusion Criteria:

  • Has an Axis I or Axis II diagnosis other than schizophrenia that has been the primary focus of treatment within 3 months of screening.
  • Has a history or current diagnosis of mental retardation, neuroleptic malignant syndrome, or any neurologic disorder, or severe head trauma.
  • Lifetime history of (HIV) positive or acquired immune deficiency syndrome (AIDS), or history of or C.
  • Any of the following:

Documented history of chromosomal disorder with developmental impairment (ie, trisomy chromosome 21; 22q11 deletion syndrome).

Evidence of any chronic organic disease of the CNS such as tumors, inflammation, active seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood- eg, Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders. In addition, subjects must not have a history of persistent neurological symptoms attributable to serious head injury. Past history of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is not exclusionary.

  • PANSS total scores ≥ 120 at screening or Baseline.
  • Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.
  • Lifetime history of electroconvulsive therapy (ECT).
  • Resistant to antipsychotic treatment based on at least two different prior adequate trials (ie, adequate dose and duration) of an antipsychotic agent within the current episode of schizophrenia.
  • neurological, metabolic (including type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, carcinoma, and/or urological disorder that would pose a risk to the subjects if they were to participate in the study or that might confound the results of the study.

Note: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if controlled) must be discussed with the Medical Monitor during screening.

  • Has a history of \< 5 years prior to signing the .
  • Clinically significant finding(s) on physical examination determined by the investigator to pose a health concern to the subject while on study.
  • Clinically relevant abnormal laboratory values or abnormal vital sign values/findings.

Note: If any laboratory results are outside the normal range, the site may have the subject retested. If upon retesting the value remains outside the normal range, the significance of this value must be discussed with the Medical Monitor for enrollment consideration.

  • A history or presence of abnormal , which in the investigator's opinion is clinically significant. Abnormal screening ECGs will be centrally over-read, and eligibility will be determined based on the over-read.
  • Presence or history (within the last year) of a medical or surgical condition (eg, gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
  • Clinically significant alcohol abuse/dependence or drug abuse/dependence based on criteria within the last 6 months prior to screening.
  • Positive test results at screening or Baseline for:

    1. Urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, cannabinoids, and methadone). A positive test for amphetamines, barbiturates, opiates, benzodiazepines or methadone may not result in exclusion of subjects if the investigator determines that the positive test is as a result of taking prescription medicine(s) as prescribed. In the event a subject tests positive for cannabinoids (tetrahydrocannabinol) or alcohol, the investigator will evaluate the subject's ability to abstain from prohibited substances during the study. If in the investigator's clinical judgment the subject will abstain, the subject may be enrolled after consultation with the Medical Monitor.
    2. Pregnancy test.
  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • Participated in another interventional clinical trial or receiving an product within 30 days prior to randomization.
  • Donation of whole blood within 60 days prior to randomization.
  • Known history or presence of clinically significant intolerance to any antipsychotic medications including but not limited to angioedema, serotonin or neuroleptic malignant syndromes.
  • Clinically relevant history of drug to lurasidone or any components in the formulation.
  • Use of concomitant medications that consistently prolong the /QTc interval within 28 days prior to randomization.
  • Received depot neuroleptics unless the last injection was at least 1 month or 1 treatment cycle prior to screening, whichever is longer.
  • Received treatment with antidepressants, stimulants, or atomoxetine within 3 days prior to randomization, fluoxetine hydrochloride within 21 days of randomization, monoamine oxidase (MAO) inhibitor within 28 days of randomization, or clozapine within 120 days of randomization.
  • Use of any antipsychotic medication (other than study drug), carbamazepine, oxcarbazepine, eslicarbazepine acetate, or fluvoxamine, within 3 days prior to randomization (7 days prior to randomization for aripiprazole) and until follow-up.
  • Has a prolactin concentration ≥ 100 ng/mL at screening, or has a history of pituitary adenoma.
  • At screening or Baseline the subject answers "yes" to "Suicidal Ideation" Items 4 or 5 on the C-SSRS.
  • Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property during the study. Subject has a history of one or more serious suicide attempts (based on the investigator's judgment) in the 3 months prior to screening. Subjects determined to be at risk of suicide or injury, as assessed by the investigator at screening, will be referred for further psychiatric evaluation.
  • Adhering to a special diet for the 28 days prior to drug administration (eg, liquid, protein, raw food diet).
  • Subject is planning to move during the study, is chronically homeless, or is unable to attend all planned study visits. The Medical Monitor will be consulted for individual cases, as needed.
  • Demonstrates a decrease (improvement) of > 25% in the PANSS score between screening and Baseline visits.
  • Subject with newly diagnosed Type 2 diabetes during screening. A subject with Type 2 diabetes is eligible for study inclusion if considered clinically stable, which is defined as:

Random (non-fasting) screening glucose is \< 200 mg/dl (11.1 mmol/L); and If ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state. Retested fasted value cannot be ≥ 126 mg/dL.

≤ 6.5%; and If a subject is currently being treated with oral anti-diabetic medication(s), the dose must have been stable for at least 4 weeks prior to screening. Such medication may be adjusted or discontinued during the study, as clinically indicated.

  • Subject has required hospitalization for diabetes or related complications in the past 12 months.
  • Subject requires use of concomitant medications that are potent inducers or inhibitors of the cytochrome P450 (CYP) 3A4 enzyme system (Appendix C) from signing informed consent until follow-up.
  • Clinically significant orthostatic hypotension (ie., a drop in systolic blood pressure of 20 mmHg or more and/or drop in diastolic blood pressure of 10 mmHg or more within 4 minutes of standing up).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
327 participants (actual)

Study arms

  • Experimental
    Lurasidone 40 mg

    Lurasidone 40 mg once daily

    Drug: Lurasidone 40 mg

  • Experimental
    Lurasidone 80 mg

    Lurasidone 80 mg once daily Arm received the Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6

    Drug: Lurasidone 80 mg

  • Placebo comparator
    Placebo

    Placebo 40 or 80 mg once daily

    Drug: Placebo 40 or 80 mg

Interventions

  • Lurasidone 40 mg once daily

    Also known as: Latuda

  • Lurasidone 80 mg once daily

    Also known as: Latuda

  • DrugPlacebo 40 or 80 mg

    Placebo 40 or 80 mg once daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6.

    PANNS total score: Changes from baseline over time - mixed model for repeated measures at week 6 -PANSS total score may range from 30 to 210- Higher values of PANSS total score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, PANSS total score at baseline, and treatment-by-visit interaction.

    Time frame: Baseline to 6 weeks

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale

    Clinical Global Impression severity (CGI-S): Changes from baseline over time-mixed model for repeated measures- scale from 1-7 - 1=normal, not at all ill; 7=among the most extremely ill patients. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, CGIS at baseline, and treatment-by-visit interaction.

    Time frame: baseline, week 6

  2. Change From Baseline in PANSS Positive Subscale Scores

    PANSS positive subscale score: changes from baseline over time - mixed model for repeated measures -Positive subscale (range 7-49): sum of Items P1 to P7 in the positive subscale - Higher values of PANSS Positive Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.

    Time frame: baseline, week 6

  3. Change From Baseline in PANSS Positive, Negative Subscale Scores

    PANSS Negative subscale score: changes form baseline over time - Mixed model for repeated measures - - Negative subscale (range 7-49): sum of Items N1 to N7 in the negative subscale - Higher values of PANSS Negative Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.

    Time frame: baseline, week 6

  4. Proportion of Responders, Where Response is Based on ≥ 20% Improvement From Baseline in PANSS Total Score at Week 6

    PANSS responder analysis over time: achieving \>= 20% reduction from baseline

    Time frame: week 6

  5. Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q)

    PQ-LES-Q percentage maximum possible score: summary statistics over time - PQ-LES-Q % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life. LS Mean and SE for change from baseline are from an ANCOVA model including factors of treatment, pooled country and age group (stratification factor), and corresponding Baseline score as covariate and LOCF approach.

    Time frame: baseline, week 6

  6. Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS)

    Clinician-rated Children's Global Assessment Scale (CGAS) score: summary statistics over time - CGAS is a numeric scale (1 through 100) , where 1 represents the most impaired functioning and 100, superior functioning LS Mean and SE for change from baseline are from an ANCOVA model including factors of treatment, pooled country and age group (stratification factor), and corresponding Baseline score as covariate and LOCF approach.

    Time frame: baseline, week 6

  7. Change From Baseline in PANSS General Psychopathology Subscale Scores

    PANSS general psychopathology subscale score: changes from baseline over time - mixed model for repeated measures -- General psychopathology (range 16-112): sum of Items G1 to G16 in the general psychopathology subscale -Higher values of PANSS General Psychopathology Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.

    Time frame: baseline, week 6

  8. Change From Baseline in PANSS Excitability Subscale Scores

    Excitability subscale scores (range 4-28): consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control * Higher values of PANSS Excitability Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.

    Time frame: baseline, week 6

07

Results

Posted Mar 22, 2017

Participant flow

Participant flow — Overall Study
MilestoneLurasidone 40 mgLurasidone 80 mgPlacebo
Started108106113
Completed969693
Not completed121020
Withdrew: Adverse event539
Withdrew: Lack of efficacy124
Withdrew: Lost to follow-up001
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject554
Withdrew: Accidental randomization001
Withdrew: Subject left study100

Outcome measures

PrimaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6.

PANNS total score: Changes from baseline over time - mixed model for repeated measures at week 6 -PANSS total score may range from 30 to 210- Higher values of PANSS total score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, PANSS total score at baseline, and treatment-by-visit interaction.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6.
units on a scaleLurasidone 40 mgLurasidone 80 mgPlacebo
baseline94.5 ± 10.9794.0 ± 11.1292.8 ± 11.08
Week 6-18.6 ± 1.59-18.3 ± 1.60-10.5 ± 1.59
Statistical analysis
  • Lurasidone 40 mg vs Placebo · LS mean difference (SE) · p = 0.0003 · Ls mean difference (se): -8.0 · 95% CI -12.4 to -3.7
  • Lurasidone 80 mg vs Placebo · LS mean difference (SE) · p = 0.0006 · Ls mean difference (se): -7.7 · 95% CI -12.1 to -3.4
SecondaryChange From Baseline in Clinical Global Impression Severity (CGI-S) Scale

Clinical Global Impression severity (CGI-S): Changes from baseline over time-mixed model for repeated measures- scale from 1-7 - 1=normal, not at all ill; 7=among the most extremely ill patients. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, CGIS at baseline, and treatment-by-visit interaction.

Time frame:
baseline, week 6
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale
units on a scaleLurasidone 40 mgLurasidone 80 mgPlacebo
baseline4.9 ± 0.624.8 ± 0.664.8 ± 0.61
week 6-0.97 ± 0.093-0.92 ± 0.093-0.50 ± 0.094
Statistical analysis
  • Lurasidone 40 mg vs Placebo · LS mean difference (SE) · p = 0.0003 · Ls mean difference (se): -0.47 · 95% CI -0.73 to -0.22
  • Lurasidone 80 mg vs Placebo · LS mean difference (SE) · p = 0.0015 · Ls mean difference (se): -0.42 · 95% CI -0.67 to -0.16
SecondaryChange From Baseline in PANSS Positive Subscale Scores

PANSS positive subscale score: changes from baseline over time - mixed model for repeated measures -Positive subscale (range 7-49): sum of Items P1 to P7 in the positive subscale - Higher values of PANSS Positive Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.

Time frame:
baseline, week 6
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Positive Subscale Scores
units on a scaleLurasidone 40 mgLurasidone 80 mgPlacebo
baseline24.1 ± 3.9624.0 ± 4.0823.4 ± 3.75
week 6-6.3 ± 0.51-6.3 ± 0.51-3.1 ± 0.51
SecondaryChange From Baseline in PANSS Positive, Negative Subscale Scores

PANSS Negative subscale score: changes form baseline over time - Mixed model for repeated measures - - Negative subscale (range 7-49): sum of Items N1 to N7 in the negative subscale - Higher values of PANSS Negative Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.

Time frame:
baseline, week 6
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Positive, Negative Subscale Scores
units on a scaleLurasidone 40 mgLurasidone 80 mgPlacebo
baseline24.2 ± 4.3224.5 ± 4.3724.4 ± 4.01
week 6-4.0 ± 0.48-3.8 ± 0.49-2.3 ± 0.49
SecondaryProportion of Responders, Where Response is Based on ≥ 20% Improvement From Baseline in PANSS Total Score at Week 6

PANSS responder analysis over time: achieving \>= 20% reduction from baseline

Time frame:
week 6
Reported as:
Number · number of participants
Proportion of Responders, Where Response is Based on ≥ 20% Improvement From Baseline in PANSS Total Score at Week 6
number of participantsLurasidone 40 mgLurasidone 80 mgPlacebo
Proportion of Responders, Where Response is Based on ≥ 20% Improvement From Baseline in PANSS Total Score at Week 6694769
SecondaryChange From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q)

PQ-LES-Q percentage maximum possible score: summary statistics over time - PQ-LES-Q % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life. LS Mean and SE for change from baseline are from an ANCOVA model including factors of treatment, pooled country and age group (stratification factor), and corresponding Baseline score as covariate and LOCF approach.

Time frame:
baseline, week 6
Reported as:
Mean · units on a scale
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q)
units on a scaleLurasidone 40 mgLurasidone 80 mgPlacebo
baseline51.3 ± 17.2653.6 ± 18.5052.5 ± 15.67
week 65.6 ± 1.286.1 ± 1.300.3 ± 1.24
SecondaryChange From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS)

Clinician-rated Children's Global Assessment Scale (CGAS) score: summary statistics over time - CGAS is a numeric scale (1 through 100) , where 1 represents the most impaired functioning and 100, superior functioning LS Mean and SE for change from baseline are from an ANCOVA model including factors of treatment, pooled country and age group (stratification factor), and corresponding Baseline score as covariate and LOCF approach.

Time frame:
baseline, week 6
Reported as:
Mean · units on a scale
Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS)
units on a scaleLurasidone 40 mgLurasidone 80 mgPlacebo
baseline44.2 ± 9.3344.6 ± 8.1143.9 ± 8.34
week 611.3 ± 1.1611.9 ± 1.187.5 ± 1.17
SecondaryChange From Baseline in PANSS General Psychopathology Subscale Scores

PANSS general psychopathology subscale score: changes from baseline over time - mixed model for repeated measures -- General psychopathology (range 16-112): sum of Items G1 to G16 in the general psychopathology subscale -Higher values of PANSS General Psychopathology Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.

Time frame:
baseline, week 6
Reported as:
Mean · units on a scale
Change From Baseline in PANSS General Psychopathology Subscale Scores
units on a scaleLurasidone 40 mgLurasidone 80 mgPlacebo
baseline46.2 ± 6.6545.5 ± 7.0345.0 ± 6.94
week 6-8.1 ± 0.80-8.1 ± 0.81-5.3 ± 0.80
SecondaryChange From Baseline in PANSS Excitability Subscale Scores

Excitability subscale scores (range 4-28): consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control * Higher values of PANSS Excitability Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.

Time frame:
baseline, week 6
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Excitability Subscale Scores
units on a scaleLurasidone 40 mgLurasidone 80 mgPlacebo
baseline10.8 ± 2.9111.1 ± 3.0710.7 ± 3.23
week 6-0.6 ± 0.33-1.7 ± 0.33-2.4 ± 0.33

Adverse events

Collected over Treatment-emergent adverse event (TEAE) is defined as an AE with a start date on or after the date of first dose through 7 days after study drug discontinuation (14 days for serious adverse events and deaths) for subjects who complete the double blind study but do not enter into the extension study or early discontinue during the double blind study), or through the last study day of the doubleblind period for subjects continuing into the extension study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 40 mg—4/110 (3.6%)70/110 (63.6%)
Lurasidone 80 mg—2/104 (1.9%)67/104 (64.4%)
Placebo—9/112 (8%)53/112 (47.3%)
Most frequent serious events
Most frequent serious events
EventLurasidone 40 mgLurasidone 80 mgPlacebo
schizophreniaPsychiatric disorders2/1102/1047/112
Homicidal IdeationPsychiatric disorders1/1100/1040/112
DiarrhoeaGastrointestinal disorders1/1100/1040/112
Psychotic DisorderPsychiatric disorders0/1100/1041/112
Suicidal IdeationPsychiatric disorders0/1100/1041/112
Most frequent other events
Most frequent other events
EventLurasidone 40 mgLurasidone 80 mgPlacebo
NauseaGastrointestinal disorders14/11015/1043/112
HeadacheNervous system disorders7/11011/10414/112
SomnolenceNervous system disorders10/11012/1046/112
AnxietyPsychiatric disorders11/1103/1049/112
AkathisiaNervous system disorders10/1109/1042/112
InsomniaPsychiatric disorders6/1107/10410/112
VomitingGastrointestinal disorders9/1107/1042/112
AgitationPsychiatric disorders5/1106/1045/112
SedationNervous system disorders6/1102/1042/112

Baseline characteristics

two subjects from the lurasidone 80mg (originally 106) group transferred to the lurasidone 40 mg (originally 108) group

Age, Categorical
Age, Categorical(Participants)Lurasidone 40 mgLurasidone 80 mgPlaceboTotal
<=18 years110104112326
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(years)Lurasidone 40 mgLurasidone 80 mgPlaceboTotal
Mean15.5 ± 1.3315.3 ± 1.3515.3 ± 1.3715.4 ± 1.35
Age, Customized
Age, Customized(Participants)Lurasidone 40 mgLurasidone 80 mgPlaceboTotal
13-15 years old505555160
16-17 years old604957166
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone 40 mgLurasidone 80 mgPlaceboTotal
Female677071208
Male433441118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lurasidone 40 mgLurasidone 80 mgPlaceboTotal
Hispanic or Latino13181344
Not Hispanic or Latino978699282
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lurasidone 40 mgLurasidone 80 mgPlaceboTotal
American Indian or Alaska Native0000
Asian64515
Native Hawaiian or Other Pacific Islander0000
Black or African American20182260
White737374220
More than one race1191131
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Lurasidone 40 mgLurasidone 80 mgPlaceboTotal
North America383537110
South America98926
Europe55761123
Southeast Asia2114
East Asia2114
Baseline BMI Percentile
Baseline BMI Percentile(participants)Lurasidone 40 mgLurasidone 80 mgPlaceboTotal
< 3th percentile0112
> 3th to 85th percentile746572211
>97th percentile66820

3 further baseline measures are reported on the registry.

08

Study locations

90 sites
  • Harmonex Neuroscience Research
    Dothan, Alabama 36303, United States
  • California Pharmaceutical Research Institute, Inc
    Anaheim, California 92804, United States
  • Central Valley Medical Research
    Bakersfield, California 93311, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Diligent Clinical Trials, Inc
    Downey, California 90241, United States
  • Collaborative Neuroscience Network, LLC
    Garden Grove, California 92845, United States
  • Global Clinical Trials, LLC
    Irvine, California 92614, United States
  • Neuropsychiatric Research Center of Orange County
    Orange, California 92868, United States
  • Asclepes Research
    Panorama City, California 91402, United States
  • CITrials, Inc. - Riverside & San Bernardino County
    Riverside, California 92506, United States
  • Hartford Hospital
    Hartford, Connecticut 06106, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34201, United States
  • Sarkis Clinical Trials - Parent
    Gainesville, Florida 32607, United States
  • APG Research, LLC
    Orlando, Florida 32803, United States
  • Medical Research Group of Central Florida
    Sanford, Florida 32771, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Institute for Behavioral Medicine, LLC
    Smyrna, Georgia 30080, United States
  • Baber Research Group
    Naperville, Illinois 60563, United States
  • Lake Charles Clinical Trials, LLC
    Lake Charles, Louisiana 70629, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Neurobehavioral Medicine Group, PLLC
    Bloomfield Hills, Michigan 48302, United States
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07753, United States
  • Manhattan Behavioral Medicine, LLC
    New York, New York 10022, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73116, United States
  • Research Strategies of Memphis, LLC
    Memphis, Tennessee 38119, United States
  • BioBehavioral Research of Austin
    Austin, Texas 78759, United States
  • Pillar Clinical Research, LLC
    Dallas, Texas 75243, United States
  • BioBehavioral Research of Austin
    El Campo, Texas 77437, United States
  • Family Psychiatry of The Woodlands, P.A.
    The Woodlands, Texas 77381, United States
  • Aspen Clinical Research
    Orem, Utah 84058, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Universitair Ziekenhuis Brussel
    Bruxelles, 1090, Belgium
  • MHC - Ruse, EOOD
    Ruse, 7003, Bulgaria
  • UMHAT "Alexandrovska" EAD
    Sofia, 1431, Bulgaria
  • MHAT-Targovishte, AD
    Targovishte, 7700, Bulgaria
  • MHAT 'Sv. Marina', EAD
    Varna, 9003, Bulgaria
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA
    Barranquilla, Colombia
  • E.S.E. Hospital Mental de Antioquia
    Bello, 0000, Colombia
  • Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda
    Bogota, 00000, Colombia
  • CHU Nantes - Hôpital Mère-Enfant
    Nantes Cedex 1, Loire Atlantique 44093, France
  • Hôpitaux Pédiatriques de Nice CHU-Lenval
    Nice, 06200, France
  • Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert
    Budapest, 1021, Hungary
  • Bekes Megyei Pandy Kalman Korhaz
    Gyula, 5700, Hungary
  • Inha University Hospital
    Incheon, 400-711, Korea, Republic of
  • Chonbuk National University Hospital
    Jeonju-si, 561-712, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 120-752, Korea, Republic of
  • University Malaya Medical Centre
    Lembah Pantai, Kuala Lumpur 59100, Malaysia
  • Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C.
    Culiacan, 80020, Mexico
  • Accelerium S. de R.L. de C.V.
    Monterrey, 64000, Mexico
  • Instituto de Informacion de Investigacion en Salud Mental
    Monterrey, 64710, Mexico
  • Alexian Brothers Health and Wellness Center
    Daveo City, 8000, Philippines
  • West Visayas State University Medical Center
    Iloilo City, 5000, Philippines
  • National Center for Mental Health
    Mandaluyong City, 1553, Philippines
  • Veterans Memorial Medical Center
    Quezon City, 1101, Philippines
  • Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu
    Torun, 87-100, Poland
  • NZOZ Poradnia Zdrowia Psychicznego
    Tyniec Maly, 55-040, Poland
  • Instytut Psychiatrii i Neurologii
    Warszawa, 02-957, Poland
  • Centro de Investigacion Clinica Psiquiatrica
    Caguas, 00725, Puerto Rico
  • Centro de Investigacion Clinica Psiquiatrica
    Ponce, 00731, Puerto Rico
  • INSPIRA Clinical Research
    San Juan, 00918, Puerto Rico
  • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
    Bucuresti, 041914, Romania
  • Spitalul Clinic de Psihiatrie Socola
    Iasi, 700282, Romania
  • Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu" Timisoara
    Timisoara, 300239, Romania
  • Sverdlov regional Psychiatric Clinical Hospital
    Ekaterinburg, 620030, Russian Federation
  • Regional Government Institution Kipetsk Regional Psychoneurology Hospital
    Lipetsk, 399083, Russian Federation
  • Nizhny Novgorod Regional State Institution of Healthcare
    Novgorod, 603155, Russian Federation
  • SHI Regional Clinical Psychiatry Hospital of St. Sofia
    Saratov, 410060, Russian Federation
  • St. Petersburg State Healthcare Institution (SPSHI)
    St. Petersburg, 190005, Russian Federation
  • FSBI "Bekhterev Psychoneurological Research Institute SPb Russia"
    St. Petersburg, 192019, Russian Federation
  • FSBSI "Scientific Research Institute of Mental Health"
    Tomsk, 634014, Russian Federation
  • Hospital Marítimo de Torremolinos
    Torremolinos, Málaga 29620, Spain
  • Hospital Sant Joan de Deu
    Barcelona, 08950, Spain
  • RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU
    Ivano Frankivsk, 76014, Ukraine
  • SI Institute of Neurology, Psychiatry and Narcology of NAMSU
    Kharkiv, 61068, Ukraine
  • SI Institute of Children and Adolescents Healthcare of NAMSU
    Kharkiv, 61153, Ukraine
  • CI Kherson Regional Psychiatric Hospital of Kherson RC
    Kherson,Vil. Stepanivka, 73488, Ukraine
  • TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions
    Kyiv, 04080, Ukraine
  • CI Lviv Regional Clinical Psychiatric Hospital
    Lviv, 79021, Ukraine
  • CI Odesa Regional Medical Center of Mental Health
    Odesa, 65006, Ukraine
  • O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy
    Poltava, 36006, Ukraine
  • Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU
    Ternopil, 46020, Ukraine
  • M.I. Pyrogov VNMU Ch of Psych&Nar BO CI O.I. Yuschenko VRPsH
    Vinnytsia, 21005, Ukraine
  • Royal Cornhill Hospital
    Aberdeen, Strathclyde AB25 2ZH, United Kingdom
  • Northcroft
    Birmingham, B23 6DW, United Kingdom
  • Royal Edinburgh Hospital
    Edinburgh, EH10 5HF, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2013
First posted
Jul 30, 2013
Start
Aug 2013
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Mar 22, 2017
Last update
Apr 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01911429
Responsible party
Sponsor
First posted
Jul 30, 2013
Start date
Aug 2013
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Mar 22, 2017
Last update
Apr 18, 2017

Study contacts

Lurasidone Medical Director
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion